-
Uncategorized3 weeks ago
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop
Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.
-
Uncategorized3 weeks ago
Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients....
-
Uncategorized3 weeks agoSTAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday. Retro has a...
-
Uncategorized3 weeks agoA federal office of men’s health has never been closer, yet it’s likely still years away
WASHINGTON — Just before he was sworn in as assistant secretary for health at the end of 2025, Admiral Brian Christine — a urologist whose practice...
-
Uncategorized3 weeks ago
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
Recorded at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with BioAge co-founder and CEO Kristen Fortney on aging biology,...
-
Uncategorized3 weeks agoOpinion: Check-in and intake at the doctor’s office are perfect for AI
I was the only person seated in the waiting room of an internal medicine specialty clinic for blood pressure issues. The day before the appointment I...
-
Uncategorized3 weeks agoMass General Brigham says it is saving more lives. Some doctors aren’t so sure.
BOSTON — In a meeting for Mass General Brigham doctors in November 2024, Dr. Giles Boland, president of Brigham and Women’s Hospital, laid out the vision for becoming...
-
Uncategorized3 weeks ago
PURE makes PURE: reconstitution of the PURE cell-free system from self-synthesized proteins
Post Content
-
Uncategorized3 weeks ago
Constructing artificial methylotrophic S. cerevisiae for chondroitin sulfate production using a multidimensional combinatorial strategy
Constructing artificial methylotrophic S. cerevisiae for chondroitin sulfate production using a multidimensional combinatorial strategy
-
Uncategorized3 weeks agoAI Designs Miniprotein Switches for GPCR Targeting
AI Designs Miniprotein Switches for GPCR Targeting
Amgen shores up Tavneos’ FDA defense with Duke data analysis
